CCHT(SZ:000661) 智通财经网·2025-09-29 08:28Core Viewpoint - Changchun High-tech (000661.SZ) announced that its subsidiary, Changchun Jinsai Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the marketing of its drug, FSH-CTP injection, in China [1] Group 1: Company Overview - The approved product is a long-acting recombinant human follicle-stimulating hormone (FSH-CTP) injection, developed by Jinsai Pharmaceutical [1] - FSH-CTP is produced using genetic engineering technology, combining the human FSH gene with the carboxy-terminal peptide of the beta subunit of human chorionic gonadotropin (hCG) gene, expressed in Chinese hamster ovary (CHO) cells [1] Group 2: Product Details - The FSH-CTP injection is designed to replace the traditional 7-day regimen of FSH injections with a single subcutaneous injection [1] - It is classified as a Class 3.2 therapeutic biological product [1]